Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.

Journal of chemotherapy (Florence, Italy) - 1 Feb 1997

Barry A L, Fuchs P C

Abstract excerpt

Grepafloxacin (OPC-17116) and three other fluoroquinolones were tested against 461 bacterial isolates representing 44 species. Grepafloxacin was superior to ciprofloxacin, ofloxacin and fleroxacin in its activity against the Gram-positive cocci, including staphylococci, pneumococci and hemolytic streptococci. Attempts to select grepafloxacin-resistant mutants from a methicillin-resistant Staphylococcus aureus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Ciprofloxacin
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enterobacteriaceae

Share to Fluoroquinolones

Share to Gram-Negative Bacteria

Share to Microbial Sensitivity Tests

Share to Mutation

Source

Identifiers

PMID: 9106012
DOI: 10.1179/joc.1997.9.1.9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.PMID 9106012Read ↗

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.Semantic proximity Read ↗

In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.Semantic proximity Read ↗

Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.Semantic proximity Read ↗

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.Semantic proximity Read ↗

Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.Semantic proximity Read ↗

The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.Semantic proximity Read ↗

Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.Semantic proximity Read ↗

Activity of and resistance to moxifloxacin in Staphylococcus aureus.Semantic proximity Read ↗

In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.Semantic proximity Read ↗

In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.Semantic proximity Read ↗

The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.Semantic proximity Read ↗

Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.